Junling Zhuang
Peking Union Medical College Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Junling Zhuang.
European Journal of Haematology | 2016
Miao Chen; Chao Liu; Junling Zhuang; Nong Zou; Ying Xu; Wei Zhang; Jian Li; Duan Mh; Tienan Zhu; Cai H; Xin-xin Cao; Shujie Wang; Daobin Zhou; Bing Han
Immunosuppressive therapy with antithymocyte immunoglobulin (ATG) and cyclosporine A is the first treatment option for severe aplastic anemia (SAA) patients without transplantation. Horse ATG is not marketed in China. Because the price of porcine ATG (pATG) is only about one‐third of the price of rabbit ATG (rATG), long‐term follow‐up studies of pATGs efficacy will help provide valuable insights into the treatment of SAA. Retrospective studies were performed to analyze the clinical information of 102 SAA patients treated with pATG and cyclosporine A from 1999 to 2014 in Peking Union Medical College Hospital. The median age was 29 years old (range 12–72). Median follow‐up time was 59.6 months (0.2–176.8). The overall response rate was 74.5% (CR 42.1%, PR 32.4%). The recurrence rate was 9.9%. The mortality rate was 16.7%. The median survival time has not been reached, and the 5‐year survival rate was 81.8%. Other hematologic abnormalities were observed in 7.8% of patients, including symptomatic PNH, MDS, and AML. Multivariate analysis revealed there was no significant effect on survival by factors such as gender, age, severity of disease, treatment time, and PNH clone (P > 0.05). These data have indicated pATG therapy combined with cyclosporine A has significant long‐term efficacy and high overall survival in SAA.
Leukemia Research | 2016
Duan Mh; Xiao Han; Jian Li; Wen Zhang; Tienan Zhu; Bing Han; Junling Zhuang; Shujie Wang; Xin-xin Cao; Cai H; Miao Chen; Chen Yang; Daobin Zhou
OBJECTIVE We compared the efficacy and clinical outcomes of vindesine and prednisone (VP) and cyclophosphamide, etoposide, vindesine, and prednisone (CEVP) regimens as first-line treatment for multisystem (MS) or multifocal single system (SS-m) adult Langerhans cell histiocytosis (LCH). METHOD Clinical features, treatment response, and survival of adults with Langerhans cell histiocytosis treated at our center from January 2001 to January 2015 were reviewed retrospectively. RESULTS Forty-five adult MS or SS-m LCH patients were treated (N=31, CEVP group; N=14, VP group). Both treatment groups had similar gender distributions, patient ages, and extent of disease. The non-active disease rate for both groups was 70.0% and 64.3% (P=0.775), respectively. Median follow-up was 74.9 (range: 2.8-183.6) months and recurrence rates were 71.0% and 78.6% (P=0.593), respectively. The need for second-line therapy was 64.5% and 71.4% (P=0.649), respectively, and mortality rates were 9.7% and 15.4% (P=0.586), respectively. Neutropenia occurred in 48.4% of CEVP-treated patients and 7.1% of VP-treated patients (P=0.008). CONCLUSIONS CEVP or VP regimens for the treatment of adult SS-m or MS LCH showed similar efficacies, and both regimens were associated with high disease recurrence and the need for second-line therapy.
Leukemia Research | 2018
Miao Chen; Chao Liu; Xinhui Qiao; Daobin Zhou; Junling Zhuang; Bing Han
Porcine anti-human lymphocyte immunoglobulin (pALG) and rabbit anti-human thymocyte immunoglobulin (rATG) are the only two ATGs for severe aplastic anemia (SAA) treatment in China. 148 treatment-naïve SAA patients who received ATG combined with cyclosporine A (CsA) therapy were analysed retrospectively. The patients were divided into a pALG group (n = 114) and a rATG group (n = 34). After three months, the pALG and rATG groups had an overall response (OR) of 65.8% and 44.1%, respectively (P = 0.023); after six months, the OR reached 74.6% and 64.7%, respectively (P = 0.361). The pALG group had markedly better time-related efficacy than the rATG group (P = 0.03). The overall survival (OS) and event-free survival (EFS) between groups had no significant difference (P > 0.1). The pALG and rATG groups did not significantly differ in terms of recurrence (8.8% vs. 5.9%, P = 0.734) or PNH clonal transformation (5.3% vs. 2.9%, P = 1.000), whereas a significant difference was found in the incidence of MDS/AML transformation (2.6% vs. 11.8%, P = 0.049). We found that pALG achieved a better time-related efficacy than rATG for the treatment of SAA; nonetheless, no significant difference in the OS or EFS of pALG compared with rATG.
Leukemia Research | 2014
Junling Zhuang; Yi Da; Hui Li; Bing Han; Xia Wan; Tienan Zhu; Miao Chen; Duan Mh; Ying Xu; Yongqiang Zhao; Ti Shen; Yongji Wu; Daobin Zhou
Journal of Infection and Chemotherapy | 2017
Xiaohan Xu; Lu Zhang; Xin-xin Cao; Jian Li; Wei Zhang; Tienan Zhu; Cai H; Miao Chen; Xiao Han; Chen Yang; Bing Han; Yan Zhang; Junling Zhuang; Daobin Zhou; Duan Mh
Chinese journal of internal medicine | 2015
Wenjiao Tang; Yi Da; Qiang Lin; Hui Li; Xin Gao; Daobin Zhou; Junling Zhuang
Annals of Hematology | 2018
Zhangbiao Long; Fan Yu; Yali Du; Hongmin Li; Miao Chen; Junling Zhuang; Bing Han
Annals of Hematology | 2018
Yan Zhang; Wei Zhang; Jian Li; Duan Mh; Bing Han; Tienan Zhu; Junling Zhuang; Cai H; Xin-xin Cao; Miao Chen; Daobin Zhou
Blood | 2012
Junling Zhuang; Yi Da; Xuan Wang; Tianjiao Li; Shujie Wang; Yongji Wu; Daobin Zhou; Yongqiang Zhao
Blood | 2005
Junling Zhuang; Yongji Wu; Xuan Wang; Wanling Sun